SEATTLE, Oct. 27, 2010 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company’s Vice President of Clinical Development, Richard T. Kenney, M.D., is presenting preclinical results from the company’s herpes simplex type 2 (HSV-2) vaccine program in a poster session Friday morning at the Keystone Symposium on Immunological Mechanisms of Vaccination (Seattle, October 27 – November 1).
